[Flomoxef in neonates and young infants; clinical efficacy, pharmacokinetic evaluation and effect on the intestinal bacterial flora]. 1991

K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
Department of Pediatrics, Asahikawa Medical College.

Forty-three newborn and young infants including 13 low-birth-weight (LBW) infants were treated with flomoxef (FMOX) and the clinical efficacy and side effect were evaluated. The ages of the patients ranged from 0 to 99 days, and their body weights from 797 to 9,000 g. Dose levels were 10.5 to 48.5 mg/kg every 6 to 8 hours for 3 to 12 days. Those patients who responded to the FMOX treatment included 8 infants with sepsis, 14 with suspected sepsis, 6 with intrauterine infection, 2 with meningitis, 7 with pneumonia, 1 with staphylococcal scalded skin syndrome, 1 with epididymitis and 4 with urinary tract infections. The results were excellent in 17 and good in 22 patients. The drug was well tolerated, although diarrhea occurred in 2, slightly elevated serum concentrations of transaminases in 2, and eosinophilia and thrombocytosis in 1 patient each. Pharmacokinetic studies on FMOX with 20 mg/kg dose were done in 19 patients including 8 LBW infants. Serum concentrations at 15 minutes after intravenous bolus injection in five 1- to 6-day-old LBW, five 1- to 6-day-old and four 8- to 19-day-old mature infants were 52.6, 52.7 and 58.0 micrograms/ml, respectively, and those at 4 hours were 22.1, 13.3 and 5.2 micrograms/ml, respectively. Serum half-lives of the drug were 3.93, 2.29 and 1.62 hours, respectively, and excretion rates of this drug into urine in the first 6 hours after administration were 30.4, 45.1 and 58.7%, respectively. Mean serum concentrations just after intravenous 1-hour drip infusion in three 8- to 54-day-old LBW and two 8- and 10-day-old mature infants, were 31.5 and 18.9 micrograms/ml, respectively, and those at 4 hours were 15.3 and 4.3 micrograms/ml, respectively. Serum half-lives of the drug were 2.88 and 1.75 hours, respectively, and excretion rates of the drug into urine in the first 6 hours were 22.6 and 47.5%, respectively. The cerebrospinal fluid level at 3 hours after a dose was 7.09 micrograms/ml on the second day of treatment in a patient with Staphylococcus aureus meningitis receiving 50 mg/kg of the drug every 6 hours per day. Its level at 1 hour after a dose was 3.52 micrograms/ml on the 8th day of treatment in the same patient. The influence of FMOX on the fecal flora was studied in 7 patients. The characteristic pattern observed during the drug administration was the disappearance of Bifidobacterium, the decrease or disappearance of Enterobacteriaceae and the preservation of Streptococcus.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007422 Intestines The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE. Intestine
D008297 Male Males
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
November 1991, The Japanese journal of antibiotics,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
November 1991, The Japanese journal of antibiotics,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
September 1986, The Japanese journal of antibiotics,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
November 1991, The Japanese journal of antibiotics,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
July 1993, The Japanese journal of antibiotics,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
September 1980, The Journal of antimicrobial chemotherapy,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
July 1993, The Japanese journal of antibiotics,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
August 1987, The Japanese journal of antibiotics,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
March 1993, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
K Fujita, and K Murono, and M Saijyo, and F Kakuya, and H Yoshioka, and S Maruyama, and H Sakata, and A Hiramoto, and F Inyaku
March 1990, The Japanese journal of antibiotics,
Copied contents to your clipboard!